FDAapproval65% confidence
FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer
Source: FDA
Why This Matters
Why this matters: provides agency context on approval that may shape timing or evidence expectations for Merck.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Infectious Disease · HIV
- Sub-indication
- General
Related signal: Merck to Present New Data on HIV Treatment Options at AIDS 2026